1 / 44

Acute lymphoblastic leukemia/lymphoma (ALL)

Acute lymphoblastic leukemia/lymphoma (ALL). A group of neoplasms of B or T lymphoblasts Pre-B cell (85%): childhood acute leukemias Pre-T cell: lymphomas in adolescent males, 50~70% with mediastinal (thymic) masses B & T : similar histology, immunophenotype

fala
Download Presentation

Acute lymphoblastic leukemia/lymphoma (ALL)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Acute lymphoblastic leukemia/lymphoma (ALL) • A group of neoplasms of B or T lymphoblasts • Pre-B cell (85%): childhood acute leukemias • Pre-T cell: lymphomas in adolescent males, 50~70% with mediastinal (thymic) masses • B & T : similar histology, immunophenotype • Chromosome anomaly (90%): hyperdiploidy, pseudodiploid, t(12;21), t(9;22), and t(4;11)

  2. BM smear: lymphoblasts

  3. Flow cytometry immunophenotype

  4. Clinical features of ALL • Blasts in BM suppress hematopoiesis by physical crowding: anemia, neutropenia, thrombocytopenia • Abrupt stormy onset • Bone pain and tenderness • Generalized lymphadenopathy (LAP), splenomegaly, hepatomegaly • CNS manifestations • Treatment (Tx) & prognosis (Px)

  5. Myeloid Neoplasms • This heterogeneous group of neoplasms is an origin in a progenitor cell that normally gives rise to terminally differentiated cells of the myeloid series (erythrocytes, granulocytes, monocytes, and platelets). • Bone marrow (BM) and other MPS • AML: immature myeloid cells in the BM • MDS: ineffective hematopoiesis & cytopenia • MPD: increased production of terminally differentiated myeloid cells

  6. Acute myelogenous leukemia (AML) • Primarily in adult: peak age, 15~39 y/o • Pathophysiology: acquired genetic alteration  inhibition of terminal differentiation  physical replacement pancytopenia • Tx: clear the BM leukemic clone (cytotoxic drugs), overcome the block in differentiation • Classification • Diagnosis: >20% myeloid blasts in BM, variable number of leukemic cells in PB (aleukemic leukemia)

  7. Revised FAB Classification of AML

  8. Proposed WHO Classification of AML

  9. BM smear: myeloblasts (M1)

  10. Flow cytometry immunophenotype

  11. Acute promyelocytic leukemia (M3)

  12. Acute monocytic leukemia (M5b)

  13. Chromosomal Abnormalities of AML • 90% AML, with prognostic implication • Ch 5 or 7 deletion: AML after MDS of CT/RT • AML M3 (APL): t(15;17)  RAR-α/PML fused gene  hybrid mRNA  abnormal retinoic acid receptor  block myeloid cell differentiation => all-trans-retinoic acid causing neoplastic promyelocytes  neutrophils (differentiation therapy), but all patients ultimately relapse

  14. Clinical Features of AML • Weeks or a few months of the onset of symptoms with findings related to pancytopenia, similar to that of ALL • APL: DIC (disseminated intravascular coagulation) • M4 &M5: infiltration of the skin (leukemia cutis) and the gingiva • localized mass composed of myeloblasts: granulocytic sarcoma (myeloblastoma, chloroma)

  15. Myelodysplastic Syndrome (MDS) • A group of clonal stem cell disorders characterized by maturation defects resulting in ineffective hematopoiesis and an increased risk of transformation to AML • BM replaced by the clonal progeny of a mutant multipotent stem cell that retains the capacity to differentiate into RBC, WBC, PLT, but in an ineffective and disordered manner • BM: hyper-/normo-cellular, PB: pancytopenia • Idiopathic (primary) or therapy-related (t-MDS)

  16. MDS • Pathogenesis: unknown (? Stem cell damage) • monosomy 5/7, 5q/7q deletions, trisomy 8, 20q deletion • MF: dysplastic differentiation & <30% blasts –BM: ring sideroblasts, megaloblastoid maturation, nuclear budding; pseudo-Pelger-Huet cells, hypo- or hyper-lobated nucleated megakaryocytes– PB: pseudo-Pelger-Huet cells, giant PLT, macrocyte, poikilocyte, monocytosis

  17. BM smear: myelodysplasia

  18. Clinical Course of MDS • Adult >60 y/o • S/S: pancytopenia, asymptomatic (half) • multiple chromosomal abnormalities and severity of cytopenia • median survival: 9~29 months (may >5 yrs) • 10~40%: AML transformation • t-MDS: 4~8 months, more grim prognosis • Tx: allogeneic BMT for younger patients; supportive treatment for the older

  19. Chronic Myeloproliferative Disorders (MPD) • A group of disorders of multipotent progenitor cell capable of terminal differentiation => hypercellular BM and increased hematopoiesis & PB counts, extramedullary hematopoiesis & splenomegaly, later in spent phase (may progress to AML, especially in CML) • CML, PCV (PV), ET, IM • non-specific pathologic findings, overlap with one another and some reactive hyperplasia • Dx: clinical+morphologic+cytogenetic

  20. Chronic Myelogenous Leukemia • Age: 25~60 y/o (peak 30+~40+y/o) • Genetics: Philadelphia chromosome (Ph1)>90% • MF: hypercellular BM with sea-blue histiocytes; leukocytosis, eosinophilia, and basophilia in PB; neoplastic extramedullary hematopoiesis (splenomegaly) • S/S: anemia, hypermetabolism, LUQ distension or pain, lack of leukocyte alkaline phosphatase • Course: slow progression (median survival 3 yrs); accelerated phase (50%)  6-12 m blast crisis  70% AML, 30% ALL (most early B lineage) • Tx: low-dose CT, allogeneic BMT (75% cure)

  21. Fluorescence in situ hybridization (FISH)

  22. FISH

  23. FISH

  24. PB smear: chronic myeloid leukemia

  25. Spleen in CML

  26. PCV: polycythemia vera • A multipotent myeloid stem cell neoplasm • absolute increase in red cell mass (Hb, Hct…) • serum erythropoietin: virtually undetectable • BM: hyperplasia  fibrosis (spent phase) • Age: 60 y/o; S/S: increased red cell mass  hematocrit  total blood volume  vascular stasis (hypertensive, cyanotic, pruritus, gout…) • risk of bleeding and thrombotic episodes • Px: 10 yrs, spent phase (M with MM), 2~15% to AML; Tx: phlebotomy

  27. Spleen in PCV

  28. ET: essential thrombocytosis • The least common form of MPD • Megakaryocytic hyperplasia: PLT>600K • Dx: by exclusion of other MPDs or reactive • BM: mild to moderate hyperplasia with marked megakaryocytic hyperplasia • PB: giant PLT, mild leukocytosis • S/S: thrombosis and hemorrhage • Px: indolent disorder, long asymptomatic periods, median survival: 12~15 yrs

  29. PB smear: ET

  30. IM: myelofibrosis with myeloid metaplasia (MMM) • Hallmark: early marrow fibrosis (myelofibrosis) • neoplastic megakaryocytes release PDGF & TGF-  fibrosis  hematopoietic stem cells seed the spleen, liver, LNs  EMH (MM) • BM: early hypercellularity, megakaryocytic hyperplasia and dysplasia, minimal fibrosis  hypocellularity, diffuse fibrosis or osteosclerosis • Spleen: huge, EMH with large, clustered megaK • PB: leukoerythroblastosis, dacryocytes

  31. PB smear: normoblast & dacryocytes

  32. Clinical Course of MMM • Age: 60 y/o or more • S/S: progressive anemia or huge spleen, hyperuricemia and secondary gout • Lab: moderate to severe anemia (normochromic and normocytic) with leukoerythroblastosis, WBC (variable) & PLT (N or elevated, then decreased) • median survival: 1~5yrs, complication: infection, thrombosis, bleeding, 5~20% to AML

  33. Langerhans cell histiocytosis (Histiocytosis X) • Clonal proliferation of the antigen-presenting dendritic cells (normal in the skin and others) • Three categories:- Letterer-Siwe disease: acute disseminated- Hand-Schuller-Christian disease: calvarial defects, diabetes insipidus, and exophthalmos- Eosinophilic granuloma • EM: HX bodies (Birbeck granules)

  34. Spleen

  35. Splenic infarcts

  36. Thymoma, benign

  37. Thymoma, invasive

More Related